Dr. Seiwert on Next Steps in Treatment of Patients With Head and Neck Cancer

Tanguy I. Seiwert, MD
Published Online: Monday, Jan 23, 2017



Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the next steps researchers are taking to improve survival outcomes for patients with head and neck cancer.

While there are the 2 FDA approvals of the PD-1 inhibitors pembrolizumab (Keytruda) and nivolumab (Opdivo) for these patients, there is still much more work to be done. Moreover, he adds, researchers are just scratching the surface as responses rates are only seen in 13% to 20% of patients.

However, there is greater potential for more of a benefit. This includes combinations of these PD-1 inhibitors with chemotherapy or other immunotherapies, he adds.
 


Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the next steps researchers are taking to improve survival outcomes for patients with head and neck cancer.

While there are the 2 FDA approvals of the PD-1 inhibitors pembrolizumab (Keytruda) and nivolumab (Opdivo) for these patients, there is still much more work to be done. Moreover, he adds, researchers are just scratching the surface as responses rates are only seen in 13% to 20% of patients.

However, there is greater potential for more of a benefit. This includes combinations of these PD-1 inhibitors with chemotherapy or other immunotherapies, he adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication